Zheng Lu, General Manager Assistant of Yangtze River Pharmaceutical Group, receives the award

On July 27, the New Medicine Forum 2013 of the 48th National New and Special Medicine Fair was held by the China Pharmaceutical News Agency, China State Institute of Pharmaceutical Industry and Reed Sinopharm Exhibition. Yangtze River Pharmaceutical Group won one of the Top 20 Innovative Pharmaceutical Companies in China.
Enhancing innovation capacity is the highest priority in realizing China's dream of building a robust pharmaceutical industry. The transformation from a giant pharmaceutical manufacturer to a giant pharmaceutical innovator is a long way ahead. Innovation was a big step for the transformation. Over the recent years, the global pharmaceutical giants were rethinking the new methods, models and values of pharmaceutical innovation and the path of "generics-hybrid-innovation" has become the consensus for the medical industry. This forum, themed "orientation, market and trend", inviting officials from various department and experts from different walks of life, discussed various topic centered on the innovative development policies of traditional Chinese medicine, path and innovation for new medicines and new trends of the cooperative research and development of new medicines.
Having made R&D and innovation the strategic basis for its development, the Company has been insisting on development through innovation and accelerating the implementation of the research and innovation strategy of "producing the three kinds of drugs simultaneously". Each year nearly 3% of the sales revenue is invested on technology and innovation by the enterprise. Based on the combination of production, study and research, Jiangsu (Yangtze River) New Drug Research Institute has been established possessing the first-class facilities and the Research and Development innovation platforms such as the state-level technological center, a key national lab which studies the new technology of pharmaceutical preparation and the national engineering research center of Chinese medicine. The Research Institute now has a professional team with almost 500 members who are capable of researching and developing new chemical drug, Chinese drug and biological drug. Through years of continuous accumulation and innovation, products of the enterprise has covered more than 10 fields and involved in 20 forms and 200 types including both Chinese and western medicine. At present, the enterprise is committed itself to the research of nearly 100 drugs used to treat serious diseases and the formation of a product echelon with the idea of “researching a batch of drugs, producing a batch of drugs and storing a batch of drugs”, thus ensuring the consistent and healthy development of the enterprise.